Serous Cystadenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: SRS001 MIFTS: 55	Serous Cystadenocarcinoma Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Serous Cystadenocarcinoma

MalaCards integrated aliases for Serous Cystadenocarcinoma:

Name: Serous Cystadenocarcinoma ¹² ¹⁵

Cystadenocarcinoma, Serous ⁴⁵ ⁷⁴

Serous Adenocarcinoma ¹² ¹⁷

Cystadenocarcinoma Serous ⁵⁶

Serous Carcinoma ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:3114

MeSH ⁴⁵ D018284

NCIt ⁵¹ C3778 C40101

SNOMED-CT ⁶⁹ 90725004

EFO ¹⁷ EFO_0003825

UMLS ⁷⁴ C0206701

Sources

Summaries for Serous Cystadenocarcinoma

Disease Ontology : ¹² A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue forming serous lesions.

MalaCards based summary : Serous Cystadenocarcinoma, also known as cystadenocarcinoma, serous, is related to uterine corpus serous adenocarcinoma and ovarian serous cystadenocarcinoma. An important gene associated with Serous Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and GPCR Pathway. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : ⁷⁷ Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma... more...

Sources

Related Diseases for Serous Cystadenocarcinoma

Diseases related to Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 273)

#	Related Disease	Score	Top Affiliating Genes
1	uterine corpus serous adenocarcinoma	33.3	ERBB2 FBXW7 PIK3CA PPP2R1A TP53
2	ovarian serous cystadenocarcinoma	32.0	AKT1 B2M ERBB2 FBXW7 HRAS MUC16
3	primary peritoneal carcinoma	31.2	ERBB2 MUC16 PGR TP53 VEGFA
4	cervical adenocarcinoma	30.5	ERBB2 PGR TP53
5	adenocarcinoma	30.5	AKT1 ERBB2 HRAS PIK3CA TP53 VEGFA
6	ovarian clear cell carcinoma	30.5	PIK3CA PPP2R1A TP53
7	in situ carcinoma	30.2	ERBB2 PGR TP53
8	testicular germ cell tumor	30.0	ALPP HRAS TP53
9	transitional cell carcinoma	29.9	ERBB2 HRAS TP53
10	carcinosarcoma	29.8	ERBB2 HRAS PGR PIK3CA TP53
11	melanoma, cutaneous malignant 1	29.8	HRAS NRAS PIK3CA TP53
12	wilms tumor 1	29.7	ERBB2 FBXW7 PGR TP53
13	cystadenocarcinoma	29.6	AKT1 ERBB2 FBXW7 HRAS MUC16 PGR
14	endometriosis	29.6	ESR2 PGR VEGFA
15	fallopian tube carcinoma	29.5	ERBB2 PGR TP53 VEGFA
16	adenomyosis	29.4	MMP2 PGR VEGFA
17	pancreatic cancer	29.2	AKT1 ERBB2 HRAS PIK3CA TP53 VEGFA
18	lymphangioleiomyomatosis	29.1	MMP14 MMP2 PGR
19	ovarian cancer 1	28.9	AKT1 ERBB2 MMP2 PIK3CA TP53 VEGFA
20	endometrial adenocarcinoma	28.6	AKT1 ERBB2 ESR2 PGR TP53 VEGFA
21	uterine carcinosarcoma	28.5	ERBB2 ESR2 FBXW7 HRAS PGR PIK3CA
22	squamous cell carcinoma	28.2	AKT1 ERBB2 HRAS MMP2 PIK3CA TP53
23	endometrial cancer	27.9	AKT1 ERBB2 ESR2 HRAS MMP2 MUC16
24	lung cancer susceptibility 3	27.5	AKT1 ERBB2 ESR2 HRAS MMP2 NRAS
25	ovarian cancer	27.0	AKT1 ALPP ERBB2 ESR2 MMP14 MMP2
26	colorectal cancer	27.0	AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
27	breast cancer	26.8	AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
28	pancreatic serous cystadenocarcinoma	12.7
29	peritoneal serous adenocarcinoma	12.3
30	fallopian tube serous adenocarcinoma	12.3
31	ovary serous adenocarcinoma	12.2
32	uterine ligament serous adenocarcinoma	12.2
33	cervical serous adenocarcinoma	12.2
34	ovarian serous carcinoma	11.6
35	papillary serous adenocarcinoma	11.3
36	ovarian cystadenocarcinoma	10.7
37	ethmoid sinus adenocarcinoma	10.5	HRAS PIK3CA
38	aggressive digital papillary adenocarcinoma	10.5	HRAS PIK3CA
39	non-proliferative fibrocystic change of the breast	10.5	ERBB2 TP53
40	melanomatosis	10.4	HRAS NRAS
41	olfactory groove meningioma	10.4	PGR TP53
42	adult hepatocellular carcinoma	10.4	PIK3CA TP53
43	giant congenital nevus	10.4	HRAS NRAS
44	malignant spiradenoma	10.4	PIK3CA TP53
45	adenoid basal cell carcinoma	10.4	B2M PGR
46	endometrium carcinoma in situ	10.4	PGR TP53
47	apocrine adenoma	10.4	HRAS PIK3CA
48	gastric papillary adenocarcinoma	10.4	ERBB2 TP53
49	prostate adenoid cystic carcinoma	10.3	HRAS PIK3CA
50	apocrine adenocarcinoma	10.3	ERBB2 PGR

Graphical network of the top 20 diseases related to Serous Cystadenocarcinoma:

Sources

Symptoms & Phenotypes for Serous Cystadenocarcinoma

GenomeRNAi Phenotypes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

²⁷

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-2	9.86	HRAS
2	Decreased viability	GR00221-A-1	9.86	AKT1 HRAS NRAS
3	Decreased viability	GR00221-A-2	9.86	AKT1 HRAS
4	Decreased viability	GR00221-A-3	9.86	AKT1 ERBB2 HRAS NRAS
5	Decreased viability	GR00221-A-4	9.86	AKT1 ERBB2
6	Decreased viability	GR00402-S-2	9.86	AKT1 ERBB2 HRAS NRAS
7	Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance	GR00210-A	9.63	ALPP ERBB2 HRAS NRAS PPP2R1A VEGFA
8	Increased cell death HMECs cells	GR00103-A-0	9.02	FBXW7 PGR PIK3CA PPP2R1A TP53

MGI Mouse Phenotypes related to Serous Cystadenocarcinoma:

⁴⁷ (show all 24)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	10.42	AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
2	homeostasis/metabolism	MP:0005376	10.39	AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
3	growth/size/body region	MP:0005378	10.38	AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
4	behavior/neurological	MP:0005386	10.36	AKT1 ERBB2 ESR2 HRAS MMP14 NRAS
5	cellular	MP:0005384	10.35	AKT1 B2M ERBB2 ESR2 FBXW7 MMP14
6	endocrine/exocrine gland	MP:0005379	10.35	AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
7	mortality/aging	MP:0010768	10.32	AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
8	integument	MP:0010771	10.3	AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
9	immune system	MP:0005387	10.28	AKT1 B2M ESR2 FBXW7 MMP14 MMP2
10	hematopoietic system	MP:0005397	10.26	AKT1 B2M ESR2 FBXW7 MMP14 MMP2
11	neoplasm	MP:0002006	10.25	AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
12	digestive/alimentary	MP:0005381	10.24	B2M ERBB2 ESR2 FBXW7 HRAS MMP14
13	embryo	MP:0005380	10.24	AKT1 ERBB2 FBXW7 MMP14 NRAS PGR
14	craniofacial	MP:0005382	10.2	ERBB2 FBXW7 HRAS MMP14 MMP2 NRAS
15	nervous system	MP:0003631	10.14	AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
16	muscle	MP:0005369	10.11	AKT1 ERBB2 ESR2 MMP14 MMP2 PGR
17	normal	MP:0002873	10.1	AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
18	limbs/digits/tail	MP:0005371	10.05	ERBB2 ESR2 MMP14 NRAS PGR TP53
19	liver/biliary system	MP:0005370	10.04	AKT1 B2M ESR2 FBXW7 NRAS TP53
20	no phenotypic analysis	MP:0003012	9.97	ESR2 HRAS MMP14 NRAS PGR PIK3CA
21	reproductive system	MP:0005389	9.91	AKT1 B2M ERBB2 ESR2 MMP14 PGR
22	respiratory system	MP:0005388	9.81	AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
23	skeleton	MP:0005390	9.7	AKT1 ERBB2 ESR2 HRAS MMP14 MMP2
24	vision/eye	MP:0005391	9.17	FBXW7 MMP14 MMP2 NRAS PIK3CA TP53

Sources

Drugs & Therapeutics for Serous Cystadenocarcinoma

Drugs for Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1

33069-62-4

36314

Carboplatin

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

41575-94-4

10339178 38904 498142

Doxorubicin

Approved, Investigational

Phase 3,Phase 2,Phase 1

23214-92-8

31703

Everolimus

Approved

Phase 2, Phase 3,Phase 1

159351-69-6

70789204 6442177

Letrozole

Approved, Investigational

Phase 2, Phase 3,Phase 3,Early Phase 1

112809-51-5

3902

Miconazole

Approved, Investigational, Vet_approved

Phase 2, Phase 3,Phase 1

22916-47-8

4189

Sirolimus

Approved, Investigational

Phase 2, Phase 3,Phase 1

53123-88-9

46835353 5284616 6436030

Docetaxel

Approved, Investigational

Phase 3,Phase 2,Phase 1

114977-28-5

148124

Bevacizumab

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

216974-75-3

Cisplatin

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

15663-27-1

2767 441203 84093

Lenograstim

Approved, Investigational

Phase 3,Phase 2,Phase 1

135968-09-1

Epirubicin

Approved

Phase 3

56420-45-2

41867

Topotecan

Approved, Investigational

Phase 2, Phase 3,Phase 3,Phase 1

119413-54-6, 123948-87-8

60700

Cyclophosphamide

Approved, Investigational

Phase 3,Phase 2,Phase 1

50-18-0, 6055-19-2

2907

Olaparib

Approved

Phase 2, Phase 3,Phase 1,Early Phase 1

763113-22-0

23725625

Gemcitabine

Approved

Phase 2, Phase 3,Phase 3,Phase 1

95058-81-4

60750

Metformin

Approved

Phase 2, Phase 3,Phase 1,Early Phase 1

657-24-9

14219 4091

Sodium Citrate

Approved, Investigational

Phase 2, Phase 3

68-04-2

Tamoxifen

Approved

Phase 2, Phase 3

10540-29-1

2733526

Trametinib

Approved

Phase 2, Phase 3,Phase 1

871700-17-3

11707110

Pembrolizumab

Approved

Phase 3,Phase 2

1374853-91-4

Atezolizumab

Approved, Investigational

Phase 2, Phase 3

1380723-44-3

Mitoxantrone

Approved, Investigational

Phase 3

65271-80-9

4212

Glutamic Acid

Approved, Nutraceutical

Phase 3,Phase 1

56-86-0

33032

Calcium

Approved, Nutraceutical

Phase 2, Phase 3

7440-70-2

271

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 2, Phase 3

77-92-9

311

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Not Applicable

59-30-3

6037

Doxil

Approved June 1999

Phase 3,Phase 2,Phase 1

31703

Maleic acid

Experimental, Investigational

Phase 2, Phase 3,Phase 1

110-17-8, 110-16-7

444972

Cediranib

Investigational

Phase 2, Phase 3,Phase 1

288383-20-0

9933475

Paclitaxel poliglumex

Experimental, Investigational

Phase 3,Phase 1

263351-82-2

Immunologic Factors

Phase 3,Phase 2,Phase 1,Not Applicable

Albumin-Bound Paclitaxel

Phase 3,Phase 2,Phase 1

Antimitotic Agents

Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1

Topoisomerase Inhibitors

Phase 3,Phase 2,Phase 1

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1

Antifungal Agents

Phase 2, Phase 3,Phase 1

Estrogens

Phase 2, Phase 3,Phase 3,Early Phase 1

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 2, Phase 3,Phase 3,Early Phase 1,Not Applicable

Hormone Antagonists

Phase 2, Phase 3,Phase 3,Early Phase 1,Not Applicable

Aromatase Inhibitors

Phase 2, Phase 3,Phase 3,Early Phase 1

Estrogen Receptor Antagonists

Phase 2, Phase 3,Phase 3,Early Phase 1

Estrogen Antagonists

Phase 2, Phase 3,Phase 3,Early Phase 1

Hormones

Phase 2, Phase 3,Phase 3,Early Phase 1,Not Applicable

Anti-Infective Agents

Phase 2, Phase 3,Phase 3,Phase 1

Steroid Synthesis Inhibitors

Phase 2, Phase 3,Phase 3,Early Phase 1

Immunosuppressive Agents

Phase 2, Phase 3,Phase 3,Phase 1

Angiogenesis Inhibitors

Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 185)

#	Name	Status	NCT ID	Phase	Drugs
1	Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer	Completed	NCT00003749	Phase 3
2	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Completed	NCT00262847	Phase 3	Carboplatin;Paclitaxel
3	Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer	Completed	NCT00006011	Phase 3	Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4	Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer	Completed	NCT00005583	Phase 3	cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
5	Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer	Completed	NCT00002568	Phase 3	cisplatin;paclitaxel
6	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	Completed	NCT00483782	Phase 3	carboplatin;paclitaxel
7	Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer	Completed	NCT00002717	Phase 3	cisplatin;paclitaxel
8	Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer	Completed	NCT00003322	Phase 3	cisplatin;paclitaxel
9	Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer	Completed	NCT00003644	Phase 3	carboplatin;paclitaxel
10	Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer	Completed	NCT00002493	Phase 3	cisplatin;doxorubicin hydrochloride
11	Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer	Completed	NCT00006027	Phase 3	cisplatin;paclitaxel
12	Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	NCT02502266	Phase 2, Phase 3	Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
13	Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	NCT00719303	Phase 3
14	Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol	Recruiting	NCT02501954	Phase 3	Cisplatin;Carboplatin;Paclitaxel
15	Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer	Recruiting	NCT03422198	Phase 3
16	Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation	Active, not recruiting	NCT03285802	Phase 2, Phase 3	Letrozole;Everolimus
17	Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer	Active, not recruiting	NCT02101788	Phase 2, Phase 3	Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
18	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Active, not recruiting	NCT00565851	Phase 3	Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
19	Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer	Active, not recruiting	NCT00108745	Phase 3	Paclitaxel;Paclitaxel Poliglumex
20	Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	Active, not recruiting	NCT01167712	Phase 3	Carboplatin;Paclitaxel
21	Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Active, not recruiting	NCT00951496	Phase 3	Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
22	Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer	Active, not recruiting	NCT02065687	Phase 2, Phase 3	Carboplatin;Metformin Hydrochloride;Paclitaxel
23	Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer	Active, not recruiting	NCT00942357	Phase 3	Carboplatin;Cisplatin;Paclitaxel
24	Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer	Active, not recruiting	NCT00807768	Phase 3	Carboplatin;Paclitaxel
25	Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer	Active, not recruiting	NCT01672892	Phase 3
26	Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer	Not yet recruiting	NCT03914612	Phase 3	Carboplatin;Paclitaxel
27	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Suspended	NCT02839707	Phase 2, Phase 3	Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
28	Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer	Terminated	NCT00003880	Phase 2, Phase 3	carboplatin;paclitaxel
29	Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer	Terminated	NCT00002819	Phase 3	carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
30	Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy	Withdrawn	NCT01492920	Phase 3
31	Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer	Unknown status	NCT02112552	Phase 2	Paclitaxel;Carboplatin
32	Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer	Unknown status	NCT02283658	Phase 2	Everolimus;Letrozole
33	VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Unknown status	NCT01666444	Phase 2	pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
34	Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer	Unknown status	NCT00017303	Phase 2	carboplatin;oglufanide disodium;paclitaxel
35	Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Unknown status	NCT00003560	Phase 2	carboplatin;docetaxel
36	Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma	Completed	NCT00506779	Phase 1, Phase 2	Imatinib Mesylate;Paclitaxel
37	Papillary Serous Carcinoma of the Endometrium	Completed	NCT00515073	Phase 2	Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
38	A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma	Completed	NCT00231868	Phase 2	Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
39	Phase II ABT-888 With Cyclophosphamide	Completed	NCT01306032	Phase 2	ABT-888;Cyclophosphamide
40	Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer	Completed	NCT00022620	Phase 2	paclitaxel
41	Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer	Completed	NCT01583322	Phase 2	vargatef;placebo
42	Uterine Papillary Serous Cancer (UPSC) Trial	Completed	NCT00147680	Phase 2	Paclitaxel, Carboplatin
43	Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer	Completed	NCT01307631	Phase 2	Akt Inhibitor MK2206
44	Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01132820	Phase 2	Cediranib Maleate
45	Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer	Completed	NCT00052312	Phase 2	cisplatin;doxorubicin hydrochloride;paclitaxel
46	AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer	Completed	NCT00275028	Phase 2	cediranib maleate
47	Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin	Completed	NCT00993616	Phase 2	belinostat;carboplatin
48	A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Completed	NCT00939809	Phase 2
49	Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy	Completed	NCT00466960	Phase 2	paclitaxel albumin-stabilized nanoparticle formulation
50	Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma	Completed	NCT00059787	Phase 2	paclitaxel;carboplatin;erlotinib

Search NIH Clinical Center for Serous Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma, serous

Sources

Genetic Tests for Serous Cystadenocarcinoma

Sources

Anatomical Context for Serous Cystadenocarcinoma

MalaCards organs/tissues related to Serous Cystadenocarcinoma:

⁴²

Ovary, Pancreas, Bone, Lymph Node, Brain, Cervix, Prostate

Sources

Publications for Serous Cystadenocarcinoma

Articles related to Serous Cystadenocarcinoma:

(show top 50) (show all 112)

#	Title	Authors	Year
1	MRI Findings of Borderline Retroperitoneal Serous Cystadenocarcinoma. ( 30823957 )	Erbay G...Parlakgumus A	2019
2	A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma. ( 30097905 )	Xiong DD...Chen G	2018
3	Gastric metastasis of ovarian serous cystadenocarcinoma. ( 30233254 )	Yang S	2018
4	Bilateral Breast and Axillary Lymph Nodes Metastases of an Ovarian Serous Cystadenocarcinoma. ( 30287996 )	Mir M...Mir A	2018
5	A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma. ( 30446011 )	Guo W...Wang Q	2018
6	Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma. ( 29456732 )	Zhang J...Wu XF	2018
7	Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma. ( 28339095 )	Cho SY...Yoo HJ	2017
8	Serous cystadenocarcinoma of the spleen. ( 28491168 )	Chou CK...Chou SC	2017
9	High Grade Serous Cystadenocarcinoma of Testis-Case Report of a Rare Ovarian Epithelial Type Tumour. ( 28764180 )	Aravind S...Balasubramanian S	2017
10	EDUCATION AND IMAGING. Hepatobiliary and Pancreatic: Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases after aggressive surgical resection. ( 26177796 )	Sasaki H...Sueda T	2016
11	Serous Cystadenocarcinoma of the Pancreas: Clinical Features and Management of a Rare Tumor. ( 26998825 )	Van Dyke TJ...Howe JR	2016
12	Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy. ( 27073511 )	Cong LX...Wang AC	2016
13	Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma. ( 27189279 )	Yang SD...Kim JI	2016
14	A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma. ( 27478834 )	Liu LW...Wang Q	2016
15	DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )	Agustriawan D...Ng KL	2016
16	Serous Cystadenocarcinoma Arising in Presumed Vitelline Duct Remnant: A Case Report and Implications in the Management of Cancer of Unknown Primary. ( 27999702 )	Lei L...Deisch JK	2016
17	Solid variant type of serous cystadenocarcinoma of the pancreas: a case report and review of the literature. ( 25716800 )	Kainuma O...Kawana H	2015
18	Synchronous resection of pancreatic serous cystadenocarcinoma and liver metastasis: First reported case and review of literature. ( 26463518 )	Machado MC...Jukemura J	2015
19	Serous Neoplasms of the Pancreas: A Clinicopathologic Analysis of 193 Cases and Literature Review With New Insights on Macrocystic and Solid Variants and Critical Reappraisal of So-called "Serous Cystadenocarcinoma". ( 26559376 )	Reid MD...Adsay V	2015
20	Primary Peritoneal Papillary Serous Cystadenocarcinoma - A Rare Malignancy. ( 26713835 )	Sahu SK...Singh SN	2015
21	"Sea anemone-like ciliated tumor cells" in a case of serous cystadenocarcinoma of the ovary. ( 26811576 )	Handa U...Mohan H	2015
22	Serous cystadenocarcinoma of the mesentery in a man: case report and review of literature. ( 24759353 )	Obuchi T...Wakabayashi G	2014
23	Neoplasms in the trocar site and peritoneal papillary serous cystadenocarcinoma. ( 25017255 )	Lai CR...Wang PH	2014
24	Paratesticular papillary serous cystadenocarcinoma: a rare entity in Indian population. ( 25308020 )	Narang V...Aulakh BS	2014
25	Histological percutaneous diagnosis of stage IV microcystic serous cystadenocarcinoma of the pancreas. ( 23370947 )	Wasel BA...Molinari M	2013
26	Ovarian serous cystadenocarcinoma metastasising to the breast. ( 23445161 )	Abehsera D...de Santiago FJ	2013
27	Serous cystadenocarcinoma of pancreas. ( 23763806 )	Rathore MU...Umair B	2013
28	IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma. ( 24595078 )	Malekzadeh M...Doroudchi M	2013
29	Serous cystadenocarcinoma of the pancreas: report of a case and management reflections. ( 22400805 )	Bramis K...Felekouras E	2012
30	Peritoneal papillary serous cystadenocarcinoma at a previous laparoscopic trocar site. ( 23040941 )	Wang LM...Shen J	2012
31	Imaging of pancreatic serous cystadenocarcinoma. ( 22009426 )	Bano S...Sakuja P	2011
32	Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen. ( 22066125 )	Cho W...Chun HK	2011
33	Testicular papillary serous cystadenocarcinoma: a rare case report and review of the literature. ( 22355499 )	Geramizadeh B...Zeighami S	2011
34	Serous cystadenocarcinoma of the pancreas with portal thrombosis. ( 20499029 )	Vadal? S...Giannone G	2010
35	Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. ( 21266826 )	Pan Y...Chen H	2010
36	Papillary serous cystadenocarcinoma of the stomach, peritoneum and ovary. ( 20163045 )	Yen CC...Yang YS	2009
37	Collision tumor: serous cystadenocarcinoma and dermoid cyst in the same ovary. ( 18818939 )	Bige O...Saygili U	2009
38	Pancreatic serous cystadenocarcinoma: a case report and review of the literature. ( 19459016 )	King JC...Hines OJ	2009
39	Serous cystadenocarcinoma of the ovary in an 11-year-old girl with extensive dissemination and chylothorax: a case report and a brief review of literature. ( 19564753 )	Gupta R...Kumar Marwah R	2009
40	Macrocystic serous cystadenocarcinoma of the pancreas: the first report of a new pattern of pancreatic carcinoma. ( 18305183 )	Gupta R...Misra MC	2008
41	Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. ( 18574502 )	Huang Y...Feng Y	2008
42	Serous cystadenocarcinoma of the pancreas with metachronous hepatic metastasis. ( 19060596 )	Franko J...Redmond J	2008
43	Plasma cell leukemia with ovarian serous cystadenocarcinoma. ( 17883177 )	Rao PS...Rai S	2007
44	Immunohistochemical identification of primary peritoneal serous cystadenocarcinoma mimicking advanced colorectal carcinoma: a case report. ( 18036260 )	von Riedenauer WB...Velanovich V	2007
45	[Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. ( 17553343 )	Yang Y...Yang HJ	2007
46	Paratesticular papillary serous cystadenocarcinoma--a case report. ( 16625973 )	Kurian RR...Belthazar A	2006
47	[Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. ( 16793610 )	Li J...Su GD	2006
48	[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. ( 17160949 )	Zhong M...Song LL	2006
49	Serous cystadenocarcinoma of the pancreas. ( 15982220 )	Shintaku M...Sakita N	2005
50	Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary. ( 16012716 )	Terauchi F...Ogura H	2005

Sources

Genes for Serous Cystadenocarcinoma

Genes related to Serous Cystadenocarcinoma (0 elite genes):

(show all 16)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	TP53	Tumor Protein P53	Protein Coding	36.29	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Variants (show sections)
2	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	29.31	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	1506732 9852392 8494699 (more) 9329572 8938479 8381375
3	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	23.39	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
4	PPP2R1A	Protein Phosphatase 2 Scaffold Subunit Aalpha	Protein Coding	23.35	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
5	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	22.98	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
6	PGR	Progesterone Receptor	Protein Coding	22.26	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	FBXW7	F-Box And WD Repeat Domain Containing 7	Protein Coding	22.23	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
8	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	22.2	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
9	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	20.24	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	ESR2	Estrogen Receptor 2	Protein Coding	20.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	19.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	ALPP	Alkaline Phosphatase, Placental	Protein Coding	18.23	GeneCards inferred via : Summaries (show sections)
13	MMP2	Matrix Metallopeptidase 2	Protein Coding	18.14	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶	8669868 11063654
14	MMP14	Matrix Metallopeptidase 14	Protein Coding	17.94	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶	11063654
15	B2M	Beta-2-Microglobulin	Protein Coding	17.8	GeneCards inferred via : Variants (show sections)
16	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	17.8	GeneCards inferred via : Variants (show sections)

Sources

Variations for Serous Cystadenocarcinoma

Sources

Expression for Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Serous Cystadenocarcinoma.

Sources

Pathways for Serous Cystadenocarcinoma

Pathways related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 132)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁷ Show member pathways Immune System ⁶⁷ Neutrophil degranulation ⁶⁷	14.07	AKT1 B2M ERBB2 FBXW7 HRAS MMP2
2	GPCR Pathway ⁶⁵ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁵ Estrogen Pathway ⁶⁵ NFAT in Immune Response ⁶⁵ P2Y Receptor Signaling ⁶⁵ Pancreatic Adenocarcinoma ⁶⁵ Paxillin Interactions ⁶⁵ Ras Pathway ⁶⁵	13.78	AKT1 ERBB2 ESR2 HRAS MMP2 NRAS
3	HIV Life Cycle ⁶⁷ Show member pathways 2-LTR circle formation ⁶⁷ APOBEC3G mediated resistance to HIV-1 infection ⁶⁷ Assembly Of The HIV Virion ⁶⁷ Binding and entry of HIV virion ⁶⁷ Disease ⁶⁷ Diseases of signal transduction ⁶⁷ Early Phase of HIV Life Cycle ⁶⁷ HIV Infection ⁶⁷ Host Interactions of HIV factors ⁶⁷ Infectious disease ⁶⁷ Integration of provirus ⁶⁷ Late Phase of HIV Life Cycle ⁶⁷	13.78	AKT1 B2M ERBB2 FBXW7 HRAS MUC16
4	TGF-Beta Pathway ⁶⁵ Show member pathways JAK-STAT Pathway ⁶⁵ JNK Pathway ⁶⁵ MAPK Family Pathway ⁶⁵ Regulation of eIF4 and p70S6K ⁶⁵ SOCS Pathway ⁶⁵	13.61	AKT1 ERBB2 HRAS NRAS PIK3CA PPP2R1A
5	Developmental Biology ⁶⁷ Show member pathways Axon guidance ⁶⁷	13.56	AKT1 ERBB2 HRAS MMP2 NRAS PIK3CA
6	Class I MHC mediated antigen processing and presentation ⁶⁷ Show member pathways Adaptive Immune System ⁶⁷ Antigen processing- Ubiquitination and Proteasome degradation ⁶⁷	13.51	AKT1 B2M ERBB2 FBXW7 HRAS NRAS
7	Response to elevated platelet cytosolic Ca2+ ⁶⁷ Show member pathways Disinhibition of SNARE formation ⁶⁷ Hemostasis ⁶⁷ Platelet activation, signaling and aggregation ⁶⁷ Platelet degranulation ⁶⁷	13.39	AKT1 HRAS NRAS PIK3CA PPP2R1A TP53
8	Nanog in Mammalian ESC Pluripotency ⁶⁵ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁵ eNOS Signaling ⁶⁵ GSK3 Signaling ⁶⁵	13.35	AKT1 ERBB2 ESR2 HRAS NRAS PPP2R1A
9	Cytokine Signaling in Immune system ⁶⁷ Show member pathways Signaling by Interleukins ⁶⁷	13.35	AKT1 B2M ERBB2 HRAS MMP2 NRAS
10	Human cytomegalovirus infection ³⁸ Show member pathways Human immunodeficiency virus 1 infection ³⁸ Kaposi sarcoma-associated herpesvirus infection ³⁸	13.04	AKT1 B2M HRAS NRAS PIK3CA TP53
11	TNFR1 Pathway ⁶⁵ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²³ Apoptosis through Death Receptors ⁶⁵ Apoptotic Pathways Triggered By HIV1 ⁶⁵ DR3 Signaling ⁶⁵ Fas Signaling ⁶⁵ GITR Pathway ⁶⁵ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶⁷ TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶⁵ TRAIL Pathway ⁶⁵ TWEAK Pathway ⁶⁵	13.03	AKT1 HRAS NRAS PIK3CA TP53 VEGFA
12	Circadian entrainment ³⁸ Show member pathways Cholinergic synapse ³⁸ Dopaminergic synapse ³⁸ Estrogen signaling pathway ³⁸ Glutamatergic synapse ³⁸ Relaxin receptors ⁶⁷ Relaxin signaling pathway ³⁸ Synaptic Neurotransmission Pathways: Glutamatergic Excitation ⁶⁶	13.02	AKT1 ESR2 HRAS MMP2 NRAS PGR
13	PI3K-Akt signaling pathway ³⁸ Show member pathways Human papillomavirus infection ³⁸	13.01	AKT1 ERBB2 HRAS NRAS PIK3CA PPP2R1A
14	Regulation of lipid metabolism Insulin signaling-generic cascades ²³ Show member pathways acetyl-CoA biosynthesis from citrate ¹ Butyrate-induced histone acetylation ¹ Cell adhesion PLAU signaling ²³ Class IB PI3K non-lipid kinase events ¹ Development CNTF receptor signaling ²³ Development Growth hormone signaling via PI3K/AKT and MAPK cascades ²³ ErbB2/ErbB3 signaling events ¹ Glucose Homeostasis ¹ Insulin signaling pathway ³⁸ IRS activation ⁶⁷ Signal attenuation ⁶⁷ Transcription Receptor-mediated HIF regulation ²³ Translation Regulation of EIF2 activity ²³ Translation Regulation of EIF4F activity ²³ Translation Insulin regulation of translation ²³	12.98	AKT1 ERBB2 HRAS NRAS PIK3CA VEGFA
15	Focal Adhesion ¹ ³⁸ Show member pathways HGF Pathway ⁶⁵ Integrin-mediated Cell Adhesion ¹	12.98	AKT1 ERBB2 HRAS NRAS PIK3CA VEGFA
16	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.95	AKT1 ERBB2 HRAS NRAS PIK3CA TP53
17	NFAT and Cardiac Hypertrophy ⁶⁵ Show member pathways IGF1R Signaling ⁶⁵ Signaling Involved in Cardiac Hypertrophy ⁶⁵	12.93	AKT1 ERBB2 HRAS NRAS PIK3CA
18	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ³⁸ Apoptosis ¹ Apoptosis and survival Apoptotic TNF-family pathways ²³ Apoptosis Signaling Pathways ⁶⁶ Death Receptor Signaling ⁶⁸	12.88	AKT1 HRAS NRAS PIK3CA TP53
19	MAPK signaling pathway ¹ ³⁸	12.85	AKT1 ERBB2 HRAS NRAS TP53 VEGFA
20	Ras signaling pathway ³⁸ Show member pathways Rap1 signaling pathway ³⁸	12.81	AKT1 HRAS NRAS PIK3CA VEGFA
21	Development HGF signaling pathway ²³ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²³ Apoptosis and survival NGF signaling pathway ²³ Apoptosis and survival Role of CDK5 in neuronal death and survival ²³ Development Neurotrophin family signaling ²³ MET activates PTPN11 ⁶⁷ MET activates STAT3 ⁶⁷ Neurotrophin signaling pathway ³⁸ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.8	AKT1 ERBB2 HRAS NRAS PIK3CA TP53
22	Downstream signaling events of B Cell Receptor (BCR) ⁶⁷ Show member pathways Activation of RAS in B cells ⁶⁷ Signaling by the B Cell Receptor (BCR) ⁶⁷	12.79	AKT1 ERBB2 HRAS NRAS PIK3CA PPP2R1A
23	4-1BB Pathway ⁶⁵ Show member pathways CD27 Pathway ⁶⁵ CD40 Signaling ⁶⁵ CMV and MAPK Pathways ⁶⁵ NF-KappaB Activation by EBV ⁶⁵ NF-kappaB Activation by Viruses ⁶⁵ PKR Pathway ⁶⁵ SUMO Pathway ⁶⁵ TNFR2 Pathway ⁶⁵	12.76	AKT1 HRAS NRAS PPP2R1A TP53
24	Gastric cancer ³⁸ Show member pathways Breast cancer ³⁸ Hepatocellular carcinoma ³⁸	12.75	AKT1 ERBB2 ESR2 HRAS NRAS PGR
25	Pathways in cancer ³⁸	12.75	AKT1 ERBB2 ESR2 HRAS MMP2 NRAS
26	Development Endothelin-1/EDNRA signaling ²³ Show member pathways Cytoskeleton remodeling FAK signaling ²³ Development Endothelin-1/EDNRA transactivation of EGFR ²³ GnRH signaling pathway ³⁸ Inflammatory mediator regulation of TRP channels ³⁸	12.72	AKT1 HRAS MMP14 MMP2 NRAS PIK3CA
27	Immune response Fc epsilon RI pathway ²³ Show member pathways Fc epsilon RI signaling pathway ³⁸ Fc-epsilon receptor I signaling in mast cells ¹ Immune response BCR pathway ²³ VEGF signaling pathway ³⁸	12.68	AKT1 HRAS NRAS PIK3CA VEGFA
28	EPH-Ephrin signaling ⁶⁷ Show member pathways Cell adhesion Ephrins signaling ²³ Cytoskeleton remodeling Fibronectin-binding integrins in cell motility ²³ EPHB forward signaling ¹ EPHB-mediated forward signaling ⁶⁷ EPH-ephrin mediated repulsion of cells ⁶⁷ Ephrin signaling ⁶⁷ EphrinB-EPHB pathway ¹ MAP kinase cascade ¹	12.65	HRAS MMP2 PIK3CA VEGFA
29	T cell receptor signaling pathway ³⁸ Show member pathways PD-L1 expression and PD-1 checkpoint pathway in cancer ³⁸ T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.63	AKT1 HRAS NRAS PIK3CA
30	Development Dopamine D2 receptor transactivation of EGFR ²³ Show member pathways Apoptosis and survival BAD phosphorylation ²³ BAD Phosphorylation ⁶⁵ Chemotaxis CXCR4 signaling pathway ²³ Development Alpha-2 adrenergic receptor activation of ERK ²³	12.62	AKT1 HRAS PIK3CA PPP2R1A
31	Immune response IL-23 signaling pathway ²³ Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁵ Development Angiopoietin - Tie2 signaling ²³ Development PDGF signaling via STATs and NF-kB ²³ IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²³ Rac1/Pak1/p38/MMP-2 pathway ¹	12.62	AKT1 ERBB2 HRAS MMP2 NRAS PIK3CA
32	ErbB signaling pathway ¹ ³⁸ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶² EGFR tyrosine kinase inhibitor resistance ³⁸ Renal cell carcinoma ³⁸ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.61	AKT1 ERBB2 HRAS NRAS PIK3CA TP53
33	MicroRNAs in cancer ³⁸	12.6	ERBB2 HRAS NRAS PIK3CA TP53 VEGFA
34	mTOR signaling pathway (KEGG) ³⁸ Show member pathways mTOR Signaling Pathway ⁶⁶	12.59	AKT1 ERBB2 HRAS NRAS PIK3CA TP53
35	Prolactin Signaling Pathway ¹ ³⁸ Show member pathways Development Prolactin receptor signaling ²³ Leptin signaling pathway ¹	12.57	AKT1 ERBB2 ESR2 HRAS NRAS PIK3CA
36	Development EGFR signaling pathway ²³ Show member pathways Development ERBB-family signaling ²³ EGF Pathway ⁶⁵ EGFR Signaling Pathway ⁶⁸ ErbB receptor signaling network ¹	12.55	AKT1 ERBB2 HRAS MMP2 NRAS PIK3CA
37	MET promotes cell motility ⁶⁷ Show member pathways Alpha 6 Beta 4 signaling pathway ¹ Laminin interactions ⁶⁷ MET activates PTK2 signaling ⁶⁷ MET activates RAP1 and RAC1 ⁶⁷ MET activates RAS signaling ⁶⁷ MET interacts with TNS proteins ⁶⁷ MET Receptor Activation ⁶⁷ MET receptor recycling ⁶⁷ Non-integrin membrane-ECM interactions ⁶⁷ Signaling by MET ⁶⁷ Syndecan interactions ⁶⁷	12.54	AKT1 HRAS NRAS PIK3CA
38	AMP-activated Protein Kinase (AMPK) Signaling ¹ Show member pathways AMPK signaling pathway ³⁸ AMPK Signaling Pathway ⁶⁸	12.53	AKT1 HRAS PIK3CA PPP2R1A TP53
39	Apoptosis Pathway ⁷³ Show member pathways Akt Pathway ⁷³ NF-kappaB Pathway ⁷³	12.52	AKT1 ERBB2 HRAS NRAS PIK3CA TP53
40	Development FGFR signaling pathway ²³ Show member pathways Development FGF-family signaling ²³ Development Flt3 signaling ²³ FGF Pathway ⁶⁵	12.51	AKT1 HRAS NRAS PIK3CA
41	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.51	AKT1 ERBB2 ESR2 HRAS MMP2 NRAS
42	VEGF Pathway (Qiagen) ⁶⁵ Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶⁵ Development VEGF-family signaling ²³ Neurophilin interactions with VEGF and VEGFR ⁶⁷ VEGF Family Ligands and Receptor Interactions ⁶⁵	12.5	AKT1 HRAS NRAS PIK3CA VEGFA
43	Phospholipase D signaling pathway ³⁸ Show member pathways Choline metabolism in cancer ³⁸	12.48	AKT1 HRAS NRAS PIK3CA
44	Development VEGF signaling via VEGFR2 - generic cascades ²³ Show member pathways Development VEGF signaling and activation ²³ VEGF - VEGF R2 Signaling Pathways ⁶⁶	12.48	AKT1 HRAS PIK3CA VEGFA
45	JAK-STAT signaling pathway (KEGG) ⁶⁶ Show member pathways Interleukin-19, 20, 22, 24 ⁶⁷ JAK-STAT signaling pathway ³⁸	12.47	AKT1 HRAS NRAS PIK3CA
46	Development IGF-1 receptor signaling ²³ Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²³ Signal transduction AKT signaling ²³	12.47	AKT1 HRAS PIK3CA TP53
47	B cell receptor signaling pathway (KEGG) ³⁸ Show member pathways B Cell Receptor Signaling Pathway ¹ BCR signaling pathway ¹	12.46	AKT1 HRAS NRAS PIK3CA
48	Human T-cell leukemia virus 1 infection ³⁸	12.45	AKT1 HRAS NRAS PIK3CA TP53
49	Oocyte meiosis ³⁸ Show member pathways Progesterone-mediated oocyte maturation ³⁸	12.43	AKT1 PGR PIK3CA PPP2R1A
50	Development Ligand-independent activation of ESR1 and ESR2 ²³ Show member pathways Transcription CREB pathway ²³ Transcription PPAR Pathway ²³	12.42	AKT1 ERBB2 ESR2 HRAS PIK3CA

Sources

GO Terms for Serous Cystadenocarcinoma

Cellular components related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	plasma membrane	GO:0005886	9.9	AKT1 ALPP B2M ERBB2 HRAS MMP14
2	mitochondrion	GO:0005739	9.5	AKT1 ESR2 FBXW7 MMP2 PGR PPP2R1A
3	membrane	GO:0016020	9.47	AKT1 ALPP B2M ERBB2 HRAS MMP14

Biological processes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 17)

#	Name	GO ID	Score	Top Affiliating Genes
1	angiogenesis	GO:0001525	9.81	MMP14 MMP2 PIK3CA VEGFA
2	positive regulation of gene expression	GO:0010628	9.77	AKT1 ERBB2 HRAS TP53 VEGFA
3	lung development	GO:0030324	9.73	FBXW7 MMP14 VEGFA
4	positive regulation of peptidyl-serine phosphorylation	GO:0033138	9.71	AKT1 PIK3CA VEGFA
5	positive regulation of cell growth	GO:0030307	9.7	AKT1 ERBB2 MMP14
6	positive regulation of endothelial cell proliferation	GO:0001938	9.67	AKT1 NRAS VEGFA
7	Ras protein signal transduction	GO:0007265	9.65	HRAS NRAS TP53
8	stimulatory C-type lectin receptor signaling pathway	GO:0002223	9.63	HRAS MUC16 NRAS
9	positive regulation of protein phosphorylation	GO:0001934	9.62	AKT1 ERBB2 HRAS VEGFA
10	positive regulation of epithelial cell proliferation	GO:0050679	9.61	ERBB2 HRAS VEGFA
11	positive regulation of MAP kinase activity	GO:0043406	9.58	ERBB2 HRAS VEGFA
12	negative regulation of macroautophagy	GO:0016242	9.57	AKT1 PIK3CA
13	anoikis	GO:0043276	9.55	AKT1 PIK3CA
14	negative regulation of Notch signaling pathway	GO:0045746	9.43	AKT1 FBXW7 MMP14
15	cytokine-mediated signaling pathway	GO:0019221	9.35	AKT1 MMP2 PIK3CA TP53 VEGFA
16	phosphatidylinositol 3-kinase signaling	GO:0014065	9.33	AKT1 ERBB2 PIK3CA
17	negative regulation of gene expression	GO:0010629	9.02	AKT1 FBXW7 HRAS PGR VEGFA

Molecular functions related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	9.86	AKT1 ALPP B2M ERBB2 ESR2 FBXW7
2	zinc ion binding	GO:0008270	9.63	ALPP ESR2 MMP14 MMP2 PGR TP53
3	identical protein binding	GO:0042802	9.23	AKT1 B2M ERBB2 ESR2 FBXW7 PGR

Sources

Sources for Serous Cystadenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia